|
[1]OKADA M, ENOMOTO M, KAWADA N, et al.Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis[J].Expert Rev Gastroenterol Hepatol, 2017, 11 (12) :1095-1104.
|
|
[2]WANG BQ, SUN YM, YOU H, et al.Pathological assessment of liver fibrosis regression[J].J Clin Hepatol, 2017, 33 (3) :435-437. (in Chinese) 王冰琼, 孙亚朦, 尤红, 等.肝纤维化逆转的病例评估[J].临床肝胆病杂志, 2017, 33 (3) :435-437.
|
|
[3]BEDOSSA P.Reversibility of hepatitis B virus cirrhosis after therapy:Who and why?[J].Liver Int, 2015, 35 (Suppl 1) :78-81.
|
|
[4]SOHRABPOUR A, MOHAMADNEJAD M, MALEKZADEH R.Review article:The reversibility of cirrhosis[J].Aliment Pharmacol Ther, 2012, 36 (9) :824-832.
|
|
[5]XU B, LIN L, XU G, et al.Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B[J].J Gastroenterol Hepatol, 2015, 30 (2) :372-378.
|
|
[6]WONG GL.Prediction of fibrosis progression in chronic viral hepatitis[J].Clin Mol Hepatol, 2014, 20 (3) :228-236.
|
|
[7]PAPACHRYSOS N, HYTIROGLOUB P, PAPALAVRENTIOS L, et al.Antiviral therapy leads to histological improvement of HBe Ag-negative chronic hepatitis B patients[J].Ann Gastroenterol, 2015, 28 (3) :374-378.
|
|
[8]TSAI NC, MARCELLIN P, BUTI M, et al.Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in asians with chronic hepatitis B[J].Dig Dis Sci, 2014, 60 (1) :260-268.
|
|
[9]European Association For The Study Of The Liver.EASL clinical practice guidelines:Management of chronic hepatitis B virus infection[J].J Hepatol, 2012, 57 (1) :167-185.
|
|
[10]SETO WK, FUNG J, CHEUNG KS, et al.Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B[J].Aliment Pharmacol Ther, 2016, 44 (10) :1071-1079.
|
|
[11]WANG Y, LIANG X, YANG JL, et al.Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of non-advanced liver fibrosis for chronic hepatitis B[J].J Viral Hepat, 2017.[Epub ahead of print]
|
|
[12]HOU JL, GAO ZL, XIE Q, et al.Tenofovir disoproxil fumaratevsadefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks:A randomized controlled trial[J].J Viral Hepat, 2015, 22 (2) :85-93.
|
|
[13]BOURLIERE M, KAHLOUN A, GASCOU-TESSONNIER G.Analogs and fibrosis regression in hepatitis B[J].Gastroenterol Clin Biol, 2009, 33 (10-11) :923-929.
|
|
[14]DUCANCELLE A, PIVERT A, BERTRAIS S, et al.Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity[J].J Gastroenterol Hepatol, 2016, 31 (10) :1750-1756.
|
|
[15]BROWN A, GOODMAN Z.Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs[J].Expert Rev Gastroenterol Hepatol, 2012, 6 (2) :187-198.
|
|
[16]HONDA K, SEIKE M, MURAKAMI K.Benefits of nucleos (t) ide analog treatments for hepatitis B virus-related cirrhosis[J].World J Hepatol, 2015, 7 (22) :2404-2410.
|
|
[17]CHANG TT, GISH R, DE MAN R, et al.A comparison of entecavir and lamivudine for HBe Ag-positive chronic hepatitis B[J].N Engl J Med, 2006, 354 (10) :1001-1010.
|
|
[18]CHIEN RN, LIAW YF.Nucleos (t) ide analogues for hepatitis B virus:Strategies for long-term success[J].Best Pract Res Clin Gastroenterol, 2008, 22 (6) :1081-1092.
|
|
[19]ZENG J, CAI S, LIU J, et al.Dynamic changes in liver stiffness measured by transient elastography predict clinical outcomes among patients with chronic hepatitis B[J].J Ultrasound Med, 2017, 36 (2) :261-268.
|
|
[20]LI X, JIE Y, YOU X, et al.Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapy[J].Int J Clin Exp, 2015, 8 (11) :21062-21070.
|
|
[21]LI ZC, CHEN ZX, WU ZY, et al.Effect of pegylated interferonα-2a combined with entecavir on hepatic function and hepatic fibrosis in patients with chronic hepatitis B[J].Anhui Med Pharm J, 2017, 21 (8) :1490-1493. (in Chinese) 李哲成, 陈朝霞, 吴昭颐, 等.聚乙二醇干扰素α-2a联合恩替卡韦对慢性乙型肝炎病人肝功能及肝纤维化的影响[J].安徽医药, 2017, 21 (8) :1490-1493.
|
|
[22]DIENSTAG JL, GOLDIN RD, HEATHCOTE EJ, et al.Histological outcome during long-term lamivudine therapy[J].Gastroenterology, 2003, 124 (1) :105-117.
|
|
[23]HADZIYANNIS SJ, TASSOPOULOS NC, HEATHCOTE EJ, et al.Long-term therapy with adefovir dipivoxilfor HBe Ag-negative chronic hepatitis B for up to 5 years[J].Gastroenterology, 2006, 131 (6) :1743-1751.
|
|
[24]JIANG JY.A following up study on postponing hepatic fibrosis in patients with chronic hepatitis B with the Fuzheng Huayu capsule plus antiviral therapy[J].Clin J Chin Med, 2017, 9 (5) :14-16. (in Chinese) 蒋金艳.扶正化瘀胶囊联合抗病毒治疗延缓慢性乙肝患者肝纤维化病变的随访研究[J].中医临床研究, 2017, 9 (5) :14-16.
|
|
[25]WANG CX, LUO WS, GUO X, et al.Systematic review of combinative effects of anluo huaxian pills with nucleotide analogues on liver fibrosis due to chronic hepatitis B[J].Chin J Exp Med Formul, 2017, 7 (21) :203-209. (in Chinese) 王晨晓, 罗伟生, 郭潇, 等.安络化纤丸联合核苷 (酸) 药物治疗慢性乙型肝炎肝纤维化的系统评价[J].中国实验方剂学杂志, 2017, 7 (21) :203-209.
|
|
[26]WU YZ, YANG L, ZHAI YF, et al.Therapeutic effect of autologous bone marrow mesenchymal stem cells on hepatic fibrosis, liver function, MELD score and 1-year survival rate in patients with decompensated hepatitis B[J].Chin J Tissue Engineer Res, 2017, 21 (12) :2049-2055. (in Chinese) 吴玉卓, 杨乐, 翟玉峰, 等.自体骨髓间充质干细胞治疗乙型肝炎失代偿期患者:肝纤维化、肝功能、MELD评分及1年生存率分析[J].中国组织工程研究, 2017, 21 (12) :2049-2055.
|
|
[27]DENG QZ, CAI T, ZHANG S, et al.Effects of autologous peripheral stem cell transplantation on acoustic radiation force impulse in patients with HBV-related decompedsated cirrhosis[J].Chin J Hepatol, 2015, 23 (11) :832-836. (in Chinese) 邓勤智, 蔡挺, 张顺, 等.自体外周血干细胞移植对乙型肝炎肝硬化失代偿期患者肝脏声脉冲辐射力成像的影响[J].中华肝脏病杂志, 2015, 23 (11) :832-836.
|
|
[28]ZHANG W, JIA JD.Pathogenesis and new therapeutic targets of liver fibrosis[J].J Clin Hepatol, 2017, 33 (3) :409-412. (in Chinese) 张伟, 贾继东.肝纤维化的发病机制及治疗新靶点[J].临床肝胆病杂志, 2017, 33 (3) :409-412.
|
|
[29]MARCELLIN P, GANE E, BUTI M, et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:A 5-year open-label follow-up study[J].Lancet, 2013, 381:468-475.
|
|
[30]HODGE A, LIM S, GOH E, et al.Coffee intake is associated with a lower liver stiffness in patients with non-alcoholic fatty liver disease, hepatitis C, and hepatitis B[J].Nutrients, 2017, 9 (1) .pii:E56.
|
DownLoad: